

Advanced Pharmaceutical Technologies for Healthcare Improvement

Prof. Maria Bryła

Professor, Medical University of Łódź, Poland

Abstract

Advanced pharmaceutical technologies are increasingly transforming drug discovery, formulation development, drug delivery, therapeutic monitoring, and personalized healthcare. The integration of nanotechnology, artificial intelligence, machine learning, computational modeling, biotechnology, advanced drug-delivery systems, 3D printing, continuous manufacturing, and digital pharmaceutical technologies has created new opportunities for improving the safety, effectiveness, precision, and accessibility of healthcare. This study examines advanced pharmaceutical technologies for healthcare improvement through a conceptual and literature-based research design. The study focuses on nanomedicine, targeted drug delivery, artificial intelligence-enabled drug discovery, personalized medicine, pharmaceutical biotechnology, 3D-printed medicines, smart drug-delivery systems, computational formulation, and advanced manufacturing technologies.

These technologies can support faster identification of therapeutic candidates, improved formulation performance, controlled drug release, targeted treatment, and individualized medication strategies. Artificial intelligence can accelerate the analysis of complex biological and pharmaceutical datasets, while nanotechnology can facilitate improved delivery of therapeutic compounds to specific biological sites. Three-dimensional pharmaceutical printing may provide opportunities for customized dosage forms, while continuous manufacturing can support process efficiency and quality consistency.

However, implementation remains associated with challenges involving regulatory requirements, manufacturing complexity, technological costs, data quality, cybersecurity, quality assurance, clinical validation, scalability, and professional acceptance. Pharmaceutical innovation must therefore combine technological advancement with rigorous scientific evaluation, patient safety, ethical responsibility, regulatory compliance, and sustainable manufacturing. The study concludes that advanced pharmaceutical technologies can significantly contribute to future healthcare improvement when integrated into evidence-based pharmaceutical development frameworks. Future research should focus on AI-supported drug discovery, precision drug delivery, nanomedicine, personalized formulations, intelligent manufacturing, digital therapeutics, and data-driven pharmaceutical quality systems.

Keywords: Pharmaceutical Technology, Drug Discovery, Drug Delivery, Nanotechnology, Artificial Intelligence, Personalized Medicine, Pharmaceutical Biotechnology, 3D Printing, Healthcare Innovation, Drug Development.

1. Introduction

The pharmaceutical sector is undergoing substantial technological transformation as emerging scientific and engineering technologies influence drug discovery, formulation, manufacturing, delivery, and therapeutic management. Conventional pharmaceutical development can require extensive time, resources, and experimental investigation before a candidate reaches clinical application. Advances in computational science, artificial intelligence, biotechnology, nanotechnology, and digital manufacturing are creating opportunities to improve different stages of the pharmaceutical development lifecycle. These technologies can support more efficient research while addressing complex healthcare requirements.

Artificial intelligence and machine learning have become important tools in pharmaceutical research because they can analyze large and complex biological, chemical, and clinical datasets. Computational approaches can support drug-target identification, molecular prediction, compound screening, formulation optimization, and therapeutic development. By identifying patterns within large datasets, intelligent systems can potentially reduce the time required for selected research activities. Nevertheless, computational predictions require experimental and clinical validation before they can be translated into reliable healthcare applications.

Advanced drug-delivery technologies represent another important area of pharmaceutical innovation. Nanoparticles, liposomes, polymeric systems, implantable technologies, and other controlled-release approaches can improve how therapeutic compounds are transported and released within the body. Targeted delivery can potentially improve therapeutic concentration at desired sites while reducing unnecessary exposure. The development of such systems requires careful evaluation of stability, toxicity, pharmacokinetics, manufacturing consistency, and clinical effectiveness.

Pharmaceutical manufacturing is also being influenced by advanced technologies. Continuous manufacturing, process analytical technologies, automation, artificial intelligence, and data-driven quality management can improve process monitoring and manufacturing efficiency. Three-dimensional printing has also created opportunities for producing customized dosage forms with potentially individualized drug combinations or release characteristics. These developments demonstrate the increasing relationship between pharmaceutical sciences, engineering, computational technologies, and healthcare delivery.

Despite these opportunities, advanced pharmaceutical technologies introduce important scientific, regulatory, ethical, and economic challenges. New technologies require appropriate validation, quality control, regulatory assessment, and long-term safety evaluation. Complex manufacturing processes can create reproducibility and scalability challenges, while AI-based systems depend on high-quality datasets. Advanced pharmaceutical solutions may also be expensive to develop and implement.

2. Objectives of the Study

2.1 Primary Objective

The primary objective of this study is to examine advanced pharmaceutical technologies and evaluate their potential contribution to healthcare improvement through innovations in drug discovery,

formulation, drug delivery, manufacturing, therapeutic personalization, and pharmaceutical quality management.

The study also aims to identify technological, scientific, regulatory, economic, and organizational factors influencing the adoption of advanced pharmaceutical technologies. Particular attention is given to artificial intelligence, nanotechnology, targeted drug delivery, pharmaceutical biotechnology, 3D printing, continuous manufacturing, computational modeling, and personalized medicine. The study seeks to establish a conceptual framework for responsible and effective pharmaceutical technology development.

2.2 Examination of Emerging Pharmaceutical Technologies

The first objective is to examine major advanced pharmaceutical technologies, including AI-supported drug discovery, nanomedicine, targeted drug-delivery systems, smart formulations, pharmaceutical biotechnology, computational modeling, 3D-printed medicines, and automated manufacturing.

The objective further evaluates how these technologies can support drug development, formulation optimization, therapeutic precision, manufacturing quality, and patient-specific medication strategies. Emphasis is placed on the convergence of pharmaceutical sciences with artificial intelligence, engineering, biotechnology, and digital technologies.

2.3 Assessment of Healthcare Improvement Applications

The second objective is to assess how advanced pharmaceutical technologies can contribute to healthcare improvement through faster drug discovery, improved drug delivery, customized formulations, enhanced manufacturing quality, optimized treatment strategies, and personalized pharmaceutical care.

The objective also identifies barriers involving regulatory approval, clinical validation, production scalability, cost, data quality, safety, manufacturing complexity, and technology adoption. Understanding these factors can support sustainable pharmaceutical innovation and improve the translation of advanced technologies into healthcare practice.

3. Review of Literature

3.1 Artificial Intelligence in Pharmaceutical Development

Artificial intelligence has become an increasingly important computational tool for pharmaceutical research. Vamathevan et al. (2019) discussed the application of machine learning throughout drug discovery and development. AI can assist with compound screening, molecular property prediction, drug-target interaction analysis, and identification of potential therapeutic candidates.

Mamoshina et al. (2018) emphasized the potential of AI and deep learning for drug discovery and development. However, AI-based pharmaceutical research depends on reliable datasets, appropriate validation, interpretable models, and experimental confirmation.

3.2 Nanotechnology and Advanced Drug Delivery

Nanotechnology has created important opportunities for improving drug delivery by enabling the development of nanoscale carriers and delivery systems. Peer, Karp, Hong, Farokhzad, Margalit, and

Langer (2007) described nanocarriers as promising tools for targeted therapeutic delivery. Nanoparticle-based systems may improve solubility, stability, circulation, and delivery of selected therapeutic compounds.

Torchilin (2014) discussed the development of multifunctional nanocarriers for targeted drug delivery. However, nanopharmaceutical development requires careful evaluation of toxicity, biodistribution, stability, manufacturing consistency, and biological interactions. Translation from laboratory research to clinical application remains a major consideration.

3.3 Personalized Medicine and Advanced Pharmaceutical Manufacturing

Personalized medicine seeks to tailor healthcare according to individual biological and clinical characteristics. Ashley (2016) discussed how genomic information can contribute to personalized healthcare. In pharmaceuticals, personalization can involve treatment selection, dosage optimization, formulation design, and patient-specific medication strategies.

Continuous manufacturing and advanced process technologies may also improve pharmaceutical production. Lee et al. (2015) examined the development of continuous pharmaceutical manufacturing as an emerging manufacturing paradigm. These approaches can support process control and potentially improve production efficiency, but require appropriate regulatory, technical, and quality-management frameworks.

4. Research Methodology

4.1 Research Design

This study adopts a conceptual and literature-based research design to examine advanced pharmaceutical technologies for healthcare improvement. The research focuses on AI-enabled drug discovery, nanotechnology, targeted drug delivery, pharmaceutical biotechnology, personalized medicine, computational formulation, 3D printing, continuous manufacturing, and digital pharmaceutical systems.

A descriptive and analytical approach is used to synthesize existing scholarly knowledge regarding technological applications and healthcare implications. The study does not present fabricated clinical trials, laboratory experiments, patient data, or pharmaceutical efficacy measurements. Instead, it develops a structured conceptual analysis of advanced pharmaceutical technologies and identifies their potential contributions, implementation requirements, and limitations.

4.2 Literature Collection and Organization

The literature was organized around major pharmaceutical innovation themes, including drug discovery, formulation, drug delivery, pharmaceutical manufacturing, nanomedicine, biotechnology, precision medicine, computational pharmaceutical research, and digital quality management.

The reviewed literature was conceptually categorized according to technological function, pharmaceutical application, healthcare contribution, development stage, and implementation requirement. Particular attention was given to technologies capable of improving efficiency, precision, safety, personalization, manufacturing consistency, and therapeutic delivery. This thematic organization supported systematic interpretation of emerging pharmaceutical technologies.

4.3 Analytical Framework

The analytical framework evaluates advanced pharmaceutical technologies through the following dimensions:

- **Drug Discovery:** AI, machine learning, computational chemistry, and molecular modeling support candidate identification.
- **Drug Design:** Computational approaches assist molecular optimization and therapeutic development.
- **Formulation Development:** Advanced modeling and engineering support dosage-form optimization.
- **Drug Delivery:** Nanocarriers, controlled-release systems, and targeted delivery technologies improve therapeutic transport.
- **Personalization:** Individual patient characteristics can inform medication selection and dosage strategies.
- **Manufacturing:** Automation and continuous manufacturing support efficient pharmaceutical production.
- **Quality Management:** Process analytics and digital monitoring support pharmaceutical quality assurance.
- **Clinical Translation:** Experimental findings require appropriate preclinical and clinical validation.
- **Regulatory Compliance:** Advanced pharmaceutical technologies must satisfy relevant safety and quality requirements.
- **Healthcare Integration:** Pharmaceutical innovation should ultimately contribute to effective, accessible, and patient-centered healthcare.

4.4 Data Analysis Approach

A thematic analytical approach was used to synthesize literature concerning advanced pharmaceutical technologies and their healthcare applications. The analysis identified recurring themes involving drug discovery, formulation, drug delivery, manufacturing, personalization, quality management, and clinical translation.

The identified themes were organized into technological, scientific, clinical, regulatory, economic, and organizational dimensions. Comparative interpretation was used to evaluate how emerging pharmaceutical technologies may contribute to healthcare improvement. Particular attention was given to safety, efficacy, scalability, manufacturing consistency, regulatory requirements, affordability, and patient-centered pharmaceutical development.

5. Analysis

5.1 Major Advanced Pharmaceutical Technologies

Advanced pharmaceutical technologies encompass a broad range of computational, biological, engineering, and manufacturing innovations. Artificial intelligence can support drug discovery and molecular analysis, while nanotechnology enables advanced delivery systems. Biotechnology contributes to biologic medicines and therapeutic development, whereas 3D printing may support

customized dosage forms. Continuous manufacturing and process analytics can improve production and quality control. summarizes major technologies and their potential pharmaceutical applications.

Table 1: Advanced Pharmaceutical Technologies and Potential Applications

Pharmaceutical Technology	Primary Capability	Potential Healthcare Application
Artificial Intelligence	Data-driven prediction	Drug discovery
Machine Learning	Pattern recognition	Molecular screening
Nanotechnology	Nanoscale delivery	Targeted therapy
Liposomal Delivery	Encapsulation	Controlled therapeutic delivery
Pharmaceutical Biotechnology	Biological production	Biologic medicines
3D Drug Printing	Customized manufacturing	Personalized dosage forms
Continuous Manufacturing	Integrated production	Manufacturing efficiency
Process Analytical Technology	Real-time monitoring	Quality assurance
Computational Modeling	Molecular simulation	Drug design
Smart Drug Delivery	Controlled release	Optimized therapy

Interpretation: demonstrates that advanced pharmaceutical technologies address multiple stages of pharmaceutical development. AI and machine learning can support drug discovery and molecular screening, while nanotechnology and liposomal systems can improve therapeutic delivery. Pharmaceutical biotechnology enables the development of biological medicines, and 3D printing creates opportunities for customized dosage forms.

Continuous manufacturing can improve production efficiency, while process analytical technology can support real-time quality monitoring. Computational modeling can assist drug design, and smart delivery systems can regulate therapeutic release. Collectively, these technologies illustrate the increasingly integrated nature of pharmaceutical science, engineering, biotechnology, and computational innovation.

5.2 Pharmaceutical Applications for Healthcare Improvement

Advanced pharmaceutical technologies can contribute to healthcare improvement by influencing drug discovery, therapeutic delivery, manufacturing, and personalized medication management. AI can accelerate selected stages of candidate identification, while targeted delivery technologies can improve

therapeutic localization. Personalized formulations may support patient-specific medication requirements. Advanced manufacturing can improve production monitoring and quality consistency. presents major applications and their potential contributions to healthcare.

Table 2: Pharmaceutical Technology Applications and Healthcare Contributions


Application Area	Advanced Technology	Potential Contribution
Drug Discovery	AI and Machine Learning	Faster candidate identification
Molecular Screening	Computational Modeling	Improved compound evaluation
Targeted Therapy	Nanotechnology	Site-specific delivery
Controlled Release	Smart Formulations	Optimized drug exposure
Personalized Medication	3D Printing	Customized dosage forms
Biologic Production	Biotechnology	Advanced therapeutic products
Manufacturing	Continuous Processing	Production efficiency
Quality Control	Process Analytics	Consistent product quality
Drug Monitoring	Digital Technologies	Treatment management
Formulation Optimization	Computational Tools	Improved pharmaceutical performance

Interpretation: shows that advanced pharmaceutical technologies can contribute to healthcare improvement through multiple interconnected applications. AI and computational modeling can support drug discovery and compound evaluation, while nanotechnology can facilitate targeted delivery. Smart formulations can regulate drug release, and 3D printing can potentially support customized dosage forms.

Biotechnology contributes to advanced biological therapeutics, while continuous processing can improve pharmaceutical manufacturing efficiency. Process analytics can strengthen quality control, and digital technologies can support treatment monitoring. Computational formulation tools may further improve pharmaceutical performance. These applications demonstrate how technological integration can support more efficient and personalized pharmaceutical development.

5.3 Advanced Pharmaceutical Innovation Framework

Figure 1: Framework for Advanced Pharmaceutical Technology Development



| HEALTHCARE IMPROVEMENT |
| Safety • Effectiveness • Precision |
| Accessibility • Patient-Centered Care |

Interpretation: The framework presents advanced pharmaceutical innovation as a structured pathway beginning with healthcare requirements and progressing through pharmaceutical research, technology development, validation, regulatory assessment, and clinical implementation. AI, nanotechnology, biotechnology, smart delivery systems, 3D printing, and automation represent important technological components.

Each innovation requires appropriate formulation, safety, quality, and performance evaluation before clinical implementation. Regulatory and quality assessment provides additional safeguards. The final objective is healthcare improvement through safer, more effective, precise, accessible, and patient-centered pharmaceutical solutions. Continuous evaluation can support refinement throughout the pharmaceutical innovation lifecycle.

6. Discussion

6.1 AI and Computational Transformation of Pharmaceutical Research

Artificial intelligence and computational technologies are changing how pharmaceutical researchers analyze biological and chemical information. Machine learning can support compound screening, molecular prediction, drug-target analysis, and optimization of selected research processes. These capabilities may reduce computational and experimental burdens in certain stages of drug development.

However, AI-based predictions should not be interpreted as independent evidence of pharmaceutical efficacy or safety. Model quality depends on data quality, representativeness, validation, and appropriate scientific interpretation. Integration between computational predictions and experimental research is therefore essential. Pharmaceutical organizations should also establish appropriate governance for AI systems to ensure transparency, reproducibility, accountability, and responsible use.

6.2 Nanotechnology and Personalized Drug Delivery

Nanotechnology offers opportunities for developing drug-delivery systems capable of modifying therapeutic distribution, release, stability, and targeting. Nanocarriers may be designed to improve delivery of compounds with specific pharmaceutical limitations. Personalized pharmaceutical approaches may further combine patient characteristics with advanced formulations and delivery systems.

Nevertheless, advanced delivery technologies require extensive characterization and evaluation. Factors such as particle properties, biological interactions, toxicity, stability, manufacturing consistency, and pharmacokinetic behavior can influence clinical outcomes. Personalized systems must also remain practical and scalable. Continued research is required to determine which technological approaches can provide meaningful improvements over established pharmaceutical delivery methods.

6.3 Advanced Manufacturing and Pharmaceutical Quality

The integration of automation, continuous manufacturing, process analytical technology, and digital monitoring can transform pharmaceutical production. Real-time process information can potentially support earlier identification of deviations and improve process control. Continuous approaches may also reduce certain inefficiencies associated with conventional batch production.

Quality should remain a central principle of advanced pharmaceutical manufacturing. Technological automation cannot compensate for inadequate process design, poor raw-material control, or insufficient validation. Manufacturers must establish robust quality systems and regulatory strategies. Workforce training is also essential because advanced manufacturing requires personnel who understand pharmaceutical science, process engineering, automation, data analysis, and quality management.

7. Challenges

7.1 Regulatory and Validation Challenges

Advanced pharmaceutical technologies can create regulatory challenges because emerging systems may differ substantially from conventional pharmaceutical processes. AI-enabled drug discovery, nanomedicine, personalized formulations, advanced manufacturing, and complex delivery systems may require specialized validation approaches.

Regulatory evaluation should address safety, quality, effectiveness, manufacturing consistency, and reproducibility. Technologies must demonstrate that their advantages are supported by reliable evidence. Developers should engage with regulatory requirements throughout the innovation process rather than treating compliance as a final-stage activity. Clear documentation, validated methods, risk assessment, and quality-by-design approaches can support responsible pharmaceutical technology development.

7.2 Manufacturing Complexity and Scalability

Laboratory-scale pharmaceutical technologies may encounter significant difficulties when transferred to commercial manufacturing. Nanoparticle systems, biological products, personalized formulations, and advanced drug-delivery technologies can require specialized equipment, controlled environments, and highly consistent production processes.

Scalability should therefore be considered from the early stages of pharmaceutical development. Manufacturing processes must demonstrate reproducibility across larger production volumes while maintaining product quality. Supply-chain requirements, raw-material consistency, equipment availability, workforce expertise, and process validation can influence scalability. Integrated collaboration between researchers, engineers, manufacturers, and quality specialists can reduce technological translation barriers.

7.3 Data Quality and AI Reliability

AI-based pharmaceutical systems depend on large datasets involving chemical structures, biological information, clinical data, and experimental results. Incomplete, biased, inconsistent, or poorly standardized data can affect model performance and reduce confidence in computational predictions.

Pharmaceutical organizations should establish appropriate data-quality management, validation, documentation, and governance procedures. AI systems should be tested using relevant datasets and independently evaluated where appropriate.

Human expertise remains essential for interpreting computational results and determining whether predictions are scientifically meaningful. Reliable data infrastructure is therefore a fundamental requirement for responsible AI integration into pharmaceutical research.

7.4 Cost, Accessibility, and Workforce Requirements

Advanced pharmaceutical technologies can involve significant investments in research infrastructure, specialized equipment, computational systems, manufacturing facilities, validation, regulatory compliance, and professional training. High development costs may affect the accessibility of innovative pharmaceutical products.

Organizations should therefore evaluate technological benefits alongside economic sustainability and healthcare needs. Workforce development is equally important because advanced pharmaceutical environments require multidisciplinary skills. Pharmacists, pharmaceutical scientists, engineers, data scientists, biotechnologists, clinicians, and regulatory specialists may need to collaborate closely. Appropriate training and institutional support can improve the successful adoption and long-term sustainability of pharmaceutical innovation.

8. Future Research

Future research should investigate integrated pharmaceutical innovation platforms combining artificial intelligence, computational chemistry, biotechnology, nanotechnology, advanced formulation science, and automated manufacturing. Such platforms could connect drug discovery with formulation optimization and manufacturing decisions. Research should examine how multimodal pharmaceutical data can improve candidate selection while maintaining scientific validity, transparency, reproducibility, and appropriate experimental verification.

Further research should focus on targeted nanomedicine, smart drug-delivery systems, personalized formulations, AI-supported molecular design, pharmaceutical 3D printing, continuous manufacturing, digital quality systems, and intelligent process monitoring. Particular attention should be given to translating laboratory innovations into scalable and clinically meaningful pharmaceutical solutions.

Future empirical studies should examine the cost-effectiveness, usability, scalability, regulatory feasibility, manufacturing performance, and patient outcomes associated with advanced pharmaceutical technologies. Research should also investigate equitable access to innovative medicines and technologies. Interdisciplinary studies involving pharmaceutical scientists, engineers, clinicians, data scientists, regulatory specialists, and patients can strengthen translational pathways and promote responsible pharmaceutical innovation.

9. Conclusion

Advanced pharmaceutical technologies are transforming multiple dimensions of pharmaceutical research and healthcare development. Artificial intelligence, machine learning, nanotechnology, biotechnology,

computational modeling, smart drug-delivery systems, 3D printing, continuous manufacturing, and process analytical technologies provide new opportunities for improving drug discovery, formulation, therapeutic delivery, manufacturing quality, and personalized medication management.

The analysis demonstrates that pharmaceutical innovation can contribute to healthcare improvement across the complete development lifecycle. AI and computational technologies can support drug discovery and molecular analysis, while nanotechnology can facilitate advanced delivery approaches. Biotechnology can contribute to complex therapeutic products, and 3D printing may enable customized dosage forms. Continuous manufacturing and process analytics can strengthen production efficiency and quality management.

However, technological advancement must be supported by rigorous validation, regulatory compliance, quality assurance, manufacturing scalability, reliable data, and appropriate clinical evidence. High development costs and specialized workforce requirements can also influence accessibility and implementation. These challenges demonstrate that pharmaceutical innovation requires coordination across scientific, technological, clinical, regulatory, and organizational domains.

Overall, advanced pharmaceutical technologies have significant potential to contribute to safer, more precise, efficient, and patient-centered healthcare. Their successful implementation depends on responsible integration of technological innovation with pharmaceutical science, clinical evidence, quality systems, and regulatory governance. Future research should continue to explore intelligent drug discovery, targeted delivery, personalized formulations, nanomedicine, advanced manufacturing, and data-driven pharmaceutical systems to strengthen the contribution of pharmaceutical innovation to future healthcare.

References

1. Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021). Advances in oral drug delivery. *Frontiers in Pharmacology*, 12, 618411. <https://doi.org/10.3389/fphar.2021.618411>
2. Andretto, V., Rosso, A., Briançon, S., & Lollo, G. (2021). Nanocomposite systems for precise oral delivery of drugs and biologics. *Drug Delivery and Translational Research*, 11, 445–470. <https://doi.org/10.1007/s13346-021-00905-w>
3. Cao, Y., et al. (2021). Nanocarriers for oral delivery of biologics: Small carriers for big payloads. *Trends in Pharmacological Sciences*. <https://doi.org/10.1016/j.tips.2021.08.005>
4. Czech, T., Lalani, R., & Oyewumi, M. O. (2019). Delivery systems as vital tools in drug repurposing. *AAPS PharmSciTech*, 20, 116. <https://doi.org/10.1208/s12249-019-1333-z>
5. Guillot, A. J., Cordeiro, A. S., Donnelly, R. F., Montesinos, M. C., Garrigues, T. M., & Melero, A. (2020). Microneedle-based delivery: An overview of current applications and trends. *Pharmaceutics*, 12(6), 569. <https://doi.org/10.3390/pharmaceutics12060569>
6. Halder, J., Gupta, S., Kumari, R., Gupta, G. D., & Rai, V. K. (2021). Microneedle array: Applications, recent advances, and clinical pertinence in transdermal drug delivery. *Drug Development and Industrial Pharmacy*, 16(3), 558–565. <https://doi.org/10.1007/s12247-020-09460-2>
7. Jain, K. K. (2020). Role of nanobiotechnology in drug delivery. *Methods in Molecular Biology*, 2059, 55–73. https://doi.org/10.1007/978-1-4939-9798-5_2

8. Jamaledin, R., Di Natale, C., Onesto, V., Baghban Taraghdari, Z., Nazarzadeh Zare, E., Makvandi, P., Vecchione, R., & Netti, P. A. (2020). Progress in microneedle-mediated protein delivery. *Journal of Clinical Medicine*, 9(2), 542. <https://doi.org/10.3390/jcm9020542>
9. Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (2020). Three-dimensional printing technology as a promising tool in bioavailability enhancement of poorly water-soluble molecules: A review. *International Journal of Pharmaceutics*, 580, 119200. <https://doi.org/10.1016/j.ijpharm.2020.119200>
10. Lee, M.-K. (2020). Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches. *Pharmaceutics*, 12(3), 264. <https://doi.org/10.3390/pharmaceutics12030264>
11. Lee, K., Goudie, M. J., Tebon, P., Sun, W., Luo, Z., Lee, J., Zhang, S., Fetah, K., Kim, H.-J., Xue, Y., Darabi, M. A., Ahadian, S., Sarikhani, E., Ryu, W., Gu, Z., Weiss, P. S., Dokmeci, M. R., & Ashammakhi, N. (2020). Non-transdermal microneedles for advanced drug delivery. *Advanced Drug Delivery Reviews*, 165–166, 41–59. <https://doi.org/10.1016/j.addr.2019.11.010>
12. Luther, D. C., Huang, R., Jeon, T., Zhang, X., Lee, Y.-W., Nagaraj, H., & Rotello, V. M. (2020). Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. *Advanced Drug Delivery Reviews*. <https://doi.org/10.1016/j.addr.2020.06.020>
13. Mohammed, A., Elshaer, A., Sareh, P., Elsayed, M., & Hassanin, H. (2020). Additive manufacturing technologies for drug delivery applications. *International Journal of Pharmaceutics*, 580, 119245. <https://doi.org/10.1016/j.ijpharm.2020.119245>
14. Pandey, M., Choudhury, H., Fern, J. L. C., Kee, A. T. K., Kou, J., Jing, J. L. J., Her, H. C., Yong, H. S., Ming, H. C., Bhattamisra, S. K., & Gorain, B. (2020). 3D printing for oral drug delivery: A new tool to customize drug delivery. *Drug Development and Industrial Pharmacy*, 10(4), 986–1001. <https://doi.org/10.1007/s13346-020-00737-0>
15. Queiroz, M. L. B., Shanmugam, S., Santos, L. N. S., Campos, C. A., Santos, A. M., Batista, M. S., Araújo, A. A. S., & Serafini, M. R. (2020). Microneedles as an alternative technology for transdermal drug delivery systems: A patent review. *Expert Opinion on Therapeutic Patents*, 30(6), 433–452. <https://doi.org/10.1080/13543776.2020.1742324>
16. Sabri, A. H., Kim, Y., Marlow, M., Scurr, D. J., Segal, J., Banga, A. K., Kagan, L., & Lee, J. B. (2020). Intradermal and transdermal drug delivery using microneedles: Fabrication, performance evaluation and application to lymphatic delivery. *Advanced Drug Delivery Reviews*, 153, 195–215. <https://doi.org/10.1016/j.addr.2019.10.004>
17. Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020). Liposomes: Advancements and innovation in the manufacturing process. *Advanced Drug Delivery Reviews*, 154–155, 102–122. <https://doi.org/10.1016/j.addr.2020.07.002>
18. Sharma, S., Hatware, K., Bhadane, P., Sindhikar, S., & Mishra, D. K. (2019). Recent advances in microneedle composites for biomedical applications: Advanced drug delivery technologies. *Materials Science and Engineering: C*, 103, 109717. <https://doi.org/10.1016/j.msec.2019.05.002>
19. Tyagi, P., & Subramony, J. A. (2018). Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small. *Journal of Controlled Release*, 272, 159–168. <https://doi.org/10.1016/j.jconrel.2018.01.009>